secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001104659-24-002537
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 2.06
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt to discontinue StrataGraft due to slow uptake; expects ~$15M in exit costs and impairment charge.
--------------------------------------------------------------------------------

- On Jan 4, 2024, committed to cease commercialization and wind down StrataGraft by end of Q1 2025.
- Pre-tax charges ~$15M excluding impairments: $5M termination benefits, $5M contract/lease termination, $5M other costs; mostly cash charges in Q1 2024.
- Impairment charge on StrataGraft inventory expected in Q1 2024 but amount not yet estimable due to fresh-start accounting from Nov 2023 bankruptcy emergence.
- Decision driven by slower-than-anticipated commercial uptake and clinical trial enrollment; evaluating sale or out-license.
- Majority of charges in Q1 2024, remainder through FY2024 and Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465924002537/0001104659-24-002537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465924002537/tm242500d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer